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Abstract. The majority of advanced prostate cancers metas-
tasise to the bone. Mediators of bone remodelling, the bone
morphogenetic proteins have extensively been implicated in
the progression and metastasis of prostate cancer. The present
study investigated the function of BMP member GDF-9, in
prostate cancer. We overexpressed GDF9 in PC-3 cells using
a mammalian expression construct, and knocked-down with
the use of ribozyme transgenes. These cells were further used
in in vitro adhesion and motility assays, in order to determine
the effect of GDF-9 on these properties. Recombinant GDF-9
was generated to treat PC-3 WT cells before further analysing
the effect on adhesion. The GDF-9 overexpressing PC-3 cells
demonstrated a significantly enhanced adhesive and motile
capacity compared to their controls. The opposite effect was
seen in the GDF-9 knock-down cells. In addition, treating
PC-3 cells with rh-GDF-9 resulted in them becoming more
adhesive. Both endogenous and exogenous GDF-9 was demon-
strated to up-regulate focal adhesion associated proteins FAK
and paxillin which contribute to promoted cell adhesion and
motility. With the use of a Smad3 inhibitor, this effect was
inhibited suggesting that GDF-9 signals via Smad3 to up-
regulate expression of these proteins. This study shows that
GDF-9 can promote the motile and adhesive capacity of
PC-3 prostate cancer cells by up-regulating expression of
FAK and paxillin in a Smad dependent manner, suggesting a
pro-tumourigenic role for GDF-9 in prostate cancer.
Introduction
Prostate cancer is the leading cancer in men of the developed
world, and is only behind lung cancer in terms of most deaths
associated with cancer (1). Metastatic prostate cancer is
accountable for the bulk of deaths associated with the disease,
and as of yet no curable treatment has been discovered. For
this reason the phenomenon of metastasis has become an
intensively studied area, and it is anticipated that a more
thorough understanding of the mechanisms behind the process
will give rise to novel therapeutic targets, capable of delaying
or preventing prostate cancer from metastasising.
Advanced prostate cancers most commonly metastasise to
the bone, where these metastases are commonly associated
with bone pain and pathological fractures. In the bone micro-
environment, bone cells are regulated by a range of different
growth factors, including the bone morphogenetic proteins
(BMPs) (2). These growth factors belong to a huge family of
proteins known as the transforming growth factor-ß (TGF-ß)
super family, a group of pleiotropic growth-factors vital in
the process of embryonic development where they regulate a
large variety of important processes including; proliferation,
apoptosis, differentiation, and invasion in an assortment of
cell types (3). Unsurprisingly then, many BMPs have been
recently shown to be involved in the progression of prostate
cancer.
In the prostate, TGF-ß plays a critical role in controlling
androgen dependence, and has been shown to induce loss of
sensitivity to hormone mediated growth inhibition, and hence
has been implicated in prostate cancer progression. BMPs
initiate their downstream signalling via two types of specific
receptors (BMPRs), known as type I and II serine/threonine
kinase receptors (4). When a BMP ligand binds to its receptors
it is capable of triggering either the Smad dependent via
Smads 1, 5 and 8, or Smads 2 and 3, or the Smad-independent
pathway via MAPK signalling (5).
The role of BMP signalling in prostate cancer has been
thoroughly researched and elucidated. In the normal prostate
for example, expression of BMP-2 and -4 is predominant, but
considerable amounts of BMP-5, -6 and -7 are also present.
When comparing to prostate cancer tissues, expression of
BMP-2 and -4 is slightly reduced, but BMP-7 expression is
significantly lower than in normal prostate sample (6).
Additionally, we have recently shown that expression of
BMP-9 and -10 is decreased or absent in prostate cancer
tissues, especially in those of a higher grade (7).
Due to the clear importance of BMPs in prostate cancer,
this study investigated the effects of a relatively unstudied
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member of the BMP family on prostate cancer cells. GDF-9
is an established oocyte growth factor vital during the early
stages of folliculogenesis and ovulation (8). Only recently
has its role in cancer been investigated. Despite this however,
GDF-9 still lacks a clear role in human cancer progression.
This study therefore aimed to determine the effects that GDF-
9 has on prostate cancer progression, and more specifically
prostate cancer cell biological properties.
Materials and methods
Materials. Mouse monoclonal anti-FAK and anti-paxillin
were obtained from BD transduction Laboratories, polyclonal
goat anti-GDF-9 antibody and rabbit anti-p-FAK, anti-p-
paxillin and anti-pSMAD3 antibodies were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). The
primers used are shown in Table I and were synthesised and
provided by Sigma-Genesis (Poole, UK).
Cell lines. The cell lines used in this study include PC-3
which was acquired from the European Collection of Animal
Cell Culture (ECACC, Salisbury, UK). The cells were
routinely maintained in DMEM-F12 medium supplemented
with 10% foetal calf serum and antibiotics.
Generation of GDF-9 ribozyme transgenes. The expression
of GDF-9 in PC-3 cells was knocked-down with the use of
anti-human GDF-9 hammerhead ribozyme transgenes,
designed by being based on the secondary structure of GDF-9
mRNA using Zuker's RNA mFold program (7). These ribo-
zymes were cloned into pEF6/His TOPO mammalian expres-
sion plasmid vectors (Invitrogen Inc., Paisley, UK). Control
empty plasmid vectors and the ribozyme transgene plasmids
were then transfected into PC-3 cells which underwent
selection with 5 μg/ml blasticidin for ~2 weeks before further
use.
Overexpression of GDF-9 in PC-3 cells. The GDF-9 coding
sequence was amplified using high fidelity PCR (LA-PCR)
with the DuraScript™ RT-PCR kit (Sigma-Aldrich, Inc.,
Poole, Dorset, UK), and was then cloned into pEF6/V5/His
vectors which was transfected into PC-3 cells. After selection
with blasticidin the cells were used for the present study.
Generation of recombinant GDF-9. 3T3 cells were trans-
fected with a GDF-9 plasmid containing a histidine tag to
help with protein purification. The HiTrap™ purification kit
(Amersham Bioscience UK Ltd., Buckinghamshire, UK) was
then used to purify Recombinant GDF-9 (rh-GDF-9) via metal
(nickel) chelating affinity chromatography.
RNA isolation, cDNA synthesis and RT-PCR. RNA was iso-
lated using the ABgene Total RNA Isolation Reagent (TRIR)
kit (ABgene, Surrey, UK). RT-PCR was then performed using
standard methods.
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Table I. PCR primer sequences.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Annealing Product
Gene Primer name Primer sequence (5'-3') temperature (˚C) size (bps)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
GDF9a GDF9aExF1 ATGGCACGTCCCAACAAAT 60-65 1362
GDF9aExR1 ATTTGACAGCAGAGGAAAAA
GDF9aExR2 TTAACGACAGGTGCACTTTGTAGC
GDF9a GDF9aRIB2F CTGCAGTAAGTGTTCAACGGTAGTAATGCCTGATGAGT 60 99
ribozyme-2 CCGTGAGG
GDF9aRIB2R ACTAGTGGAACTGCTATTTAACCTGGATTTCGTCCTCA
CGGACT
GDF9a GDF9aRIB3F CTGCAGCTGTGATAAGCCTGAGCACTTGTGTCATTCAA 62 102
ribozyme-3 ATATAACTGATGAGTCCGTGAGGA
GDF9aRIB3R ACTAGTTTTAACATGACTCTGGTGTCCCCCTCACTGAT
TTCGTCCTCACGGACT
GDF9 GDF9F9 GCGCTTTTCAAAGTTCTATC 56 432
GDF9R9 GGTCACATCAATCTGAATCC
FAK FAKF1 AACAGGTGAAGAGCGATTAT 56 99
FAKzR ACTGAACCTGACCGTACACAGTATGATCGCCGTATTTC
Paxillin PaxF1 CAATCCTTGACCCCTTAGA 56 115
PaxzR ACTGAACCTGACCGTACATTGGAGACACTGGAAGTTTT
ß-actin BactF ATGATATCGCCGCGCTCG 55 580
BactR CGCTCGGTGAGGATCTTCA
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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SDS-PAGE and Western blot analysis. Protein samples were
separated on a 10% polyacrylamide gel, and following SDS-
PAGE, were transferred onto nitrocellulose membranes.
These membranes were blocked and probed with the specific
primary (1:250) and corresponding peroxidise-conjugated
secondary antibodies (1:1000) for 1 h, respectively. The
resulting bands were finally visualised using the Supersignal™
West Dura system (Pierce Biotechnology, USA).
Immuno-fluorescent staining of pSmad3. The cells were
blocked, and probed with anti-pSmad3 primary antibody
followed by corresponding FITC-labelled secondary anti-
body at a concentration of 1:100. The staining was visualised
using the Olympus BX51 fluorescent microscope.
In vitro cell-matrix adhesion assay. The procedure was
carried out as previously described (9). Cells (40000) were
seeded into a 96-well plate pre-coated with 5 μg/ml of
Matrigel™. The cells were left to adhere to the Matrigel for a
period of 40 min, following which the adherent cells stained
with crystal violet and counted.
In vitro cytodex-2 bead motility assay. The procedure was
carried out as previously described (9). The cells were
incubated with cytodex-2 beads and left over night, by which
time the cells had adhered to the surface of the beads. The
beads carrying the cells were then transferred into a 24-well
plate, where the cells move from the beads onto the surface
of the culture plate. These cells were then stained with crystal
violet and counted.
Stastical analysis. Statistical analysis was carried out using
Minitab® version 14. The Mann-whitney test was used for
non-normally distributed data and the two sample T test was
used for normally distributed data.
Results
Effect of GDF-9 on prostate cancer cell adhesion. GDF-9
overexpression and knock-down was confirmed in PC-3 cells
at both the mRNA and protein level using RT-PCR and
Western blotting. PC-3GDF-9exp. cells demonstrated signifi-
cantly higher expression levels of GDF-9 compared to PC-3WT
and PC-3pEF, whereas PC-3GDF-9rib3 demonstrated reduced
levels (Fig. 1A and B).
The cells were further analysed for their adhesive capacity
in an in vitro adhesion assay, where a significantly larger
number of PC-3GDF-9exp. cells (70.5±12.1) had adhered to the
Matrigel, p<0.01 compared to PC-3WT (46.0±10.9) and PC-3pEF
(32.67±6.71) controls (Fig. 2A). In contrast, a reduction in the
number of adhered cells was seen in PC-3GDF-9rib3 (20.85±2.03)
cells, p<0.01 compared to both PC-3WT (46.02±7.84) and
PC-3pEF (32.60±7.53) (Fig. 2B).
In order to further examine the effect of GDF-9 on prostate
cancer cells, recombinant GDF-9 (rh-GDF-9) was generated
using 3T3 cells with overexpressed GDF-9 (3T3GDF-9N4exp.)
(Fig. 1C). After 40-min exposure to 20 ng/ml of rh-GDF-9, the
cells were stained with crystal violet and counted. These
treated cells demonstrated a significantly increased adhesi-
veness (50.07±4.89) in comparison to the untreated cells
(37.33±2.09), p=0.05 (Fig. 2C).
Influence on motility of prostate cancer cells by GDF-9. The
cells were additionally evaluated for their motility using a
cytodex-2 bead motility assay. GDF-9 overexpression demon-
strated enhanced cell motility compared to the controls. A
significantly larger proportion of PC-3GDF-9exp. cells (99.2±16.1)
had migrated from the beads onto the surface of the culture
plate in comparison with the PC-3WT (64.1±10.0) and PC-3pEF
(76.56±2.22) controls, p=0.049 vs. PC-3WT and 0.073 vs.
PC-3pEF (Fig. 3A). In contrast, the GDF-9 knock-down cells
demonstrated reduced cell motility compared to these
controls. The number of migrating cells in PC-3GDF-9rib3 was
(29.67±2.00), p<0.05 and p<0.01 compared to PC-3WT and
PC-3pEF, respectively (Fig. 3B).
GDF-9 up-regulates expression of FAK and paxillin. With the
intention of determining a mechanism by which GDF-9 can
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Figure 1. Verification of GDF-9 overexpression and knock-down in PC-3
cells. (A) mRNA level using PCR and (B) protein level using Western blot
analysis. (C) Western blot analysis verifying purification of rh-GDF-9 from
3T3 transfectants after desaltification; a, is the GDF-9 proprotein (70
kDa), b, the precursor protein (57 kDa), c, the mature ligand dimer (40
kDa); and d, the mature monomer (18 kDa). M refers to the molecular
marker, lane 1 is 3T3pEF conditioned media, 2 is 3T3GDF-9N4exp. conditioned
media, 3 is 1 μm imidazole (elution buffer used for recombinant protein
purification), 4 is rh-GDF-9 elution 1 and 5 is rh-GDF-9 elution 2.
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promote prostate cancer cell adhesion and motility, the
expression levels of well-established adhesion molecules
FAK and paxillin were analysed at both the mRNA and
protein level. PC-3GDF-9exp. cells demonstrated increased expres-
sion of both FAK and paxillin compared to both controls
(Fig. 4A and B). In addition, PC-3GDF-9rib3 cells had similar
mRNA levels of both molecules to the controls.
To further confirm this hypothesis, PC-3 WT cells were
treated with rh-GDF-9 for varying amounts of time to see if
exogenous GDF-9 would have a similar effect on FAK and
paxillin expression. Using PCR and Western blot analysis,
expression levels of FAK and paxillin were analysed. Levels
of FAK and paxillin mRNA were increased after only half an
hour of treatment with rh-GDF-9 (Fig. 4C). In the case of
protein levels however, expression of paxillin was only
increased after 4 h treatment and that of FAK only after 24 h
(Fig. 4D). Furthermore, protein levels of phosphorylated and
hence activated FAK and paxillin (p-FAK and p-paxillin),
were analysed in order to determine if GDF-9 not only up-
regulates but also activates these molecules. Indeed, levels of
p-FAK and p-paxillin were up-regulated at similar time-
points as their non-phosphorylated counterparts compared to
the untreated controls, suggesting that GDF-9 not only up-
regulates expression of FAK and paxillin but also activates
them.
GDF-9 signals via Smad dependent pathway using Smad3.
BMPs can signal via two different pathways, Smad-dependent
or Smad-independent. Previous literature suggests that
GDF-9 signals through ALK-5 and BMPR-II via Smads 2
and 3 in the oocyte (10). In order to determine if the same is
true in prostate cancer cells, the effect of GDF-9 on the serine/
threonine phosphorylation of Smad3 was investigated. Levels
of pSmad3 were first examined in the GDF-9 overexpressing
cells using immuno-fluorescent staining (Fig 5B). PC-3GDF-9exp.
cells demonstrated significantly stronger nuclear staining of
pSmad3 compared to controls. To further confirm the involve-
ment of Smad3 in GDF-9 signalling in prostate cancer cells,
PC-3 cells were treated with 20 ng/ml rh-GDF-9 for different
periods of time, after which protein levels of pSmad3 and
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Figure 2. Effect of GDF-9 on in vitro cell adhesion of PC-3 cells. (A) The
adhesive capacity of PC-3GDF-9exp. cells was significantly increased in
comparison to controls. (B) Knocking-down GDF-9 inhibited PC-3 adhesive
capacity. (C) The adhesive capacity of PC-3 cells was increased when
treated with rh-GDF-9, compared to the non-treated cells. Data shown are
representative of at least 3 independent repeats. *p<0.01 compared to both
controls (n=6).
Figure 3. Effect of GDF-9 on in vitro cell motility of PC-3 cells. (A) The
motility of PC-3GDF-9exp. cells was increased. *p<0.05. (B) GDF-9 knock-
down cells showed reduced motility. *p<0.01. Data shown are representative
of at least 3 independent repeats (n=6).
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total Smad3 were analysed by Western blot analysis (Fig. 5A).
Expression of pSmad3 protein was up-regulated by rh-GDF-9
after only 1 h of treatment while levels of non-phosphorylated
Smad3 remained unchanged.
The Smad3 inhibitor prevents phosphorylation and
hence activation of Smad3, and when treating PC-3 WT cells
with this inhibitor, the up-regulation in pSmad3 expression
seen with rh-GDF-9 treatment was inhibited (Fig. 5C).
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Figure 4. Effect of GDF-9 on FAK and paxillin. (A) PCR demonstrating increased mRNA levels of FAK and (B) paxillin in the PC-3GDF-9exp. cells compared
to controls and knock-down cells. (C) PC-3 cells treated with 20 ng/ml rh-GDF-9 had increased expression of FAK and paxillin at the mRNA level with PCR,
and (D) protein level using Western blot analysis, compared to controls. In addition, activated forms of both FAK and paxillin (p-FAK and p-paxillin) were
increased when treated with rh-GDF-9. Imidazole (1 μM) was used as a control as it was used as the elution buffer during metal affinity chromatography and
purification of rh-GDF-9.
Figure 5. GDF-9 signalling via Smad3. (A) PC-3 cells treated with rh-GDF-9 demonstrated increased pSmad3 protein levels compared to control. Levels of
total Smad3 remained unchanged. (B) IFC staining demonstrating increased levels of nuclear pSmad3 staining in the PC-3GDF-9exp. cells. (C) Western blot
analysis showing PC-3 cells treated with Smad3 inhibitor resulting in reduced expression of pSmad3. (D) Treating cells with Smad3 inhibitor resulted in
inhibition of GDF-9 associated promoted adhesion.
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Additionally, when these cells were exposed to Smad3
inhibitor along with rh-GDF-9 (33.1±7.18), the previously
seen GDF-9 associated increase in cellular adhesion
(86.9±4.76) was inhibited, suggesting that GDF-9 signals via
Smad3 to exert its effects on prostate cancer cell adhesion,
p=0.002 compared to PC-3 treated with rh-GDF-9 and p=0.027
vs. untreated control (Fig. 5D).
GDF-9 up-regulates FAK and paxillin by signalling via
Smad3. In order to establish whether GDF-9 up-regulation of
FAK and paxillin is due to Smad3 signalling, PC-3 cells were
treated with 20 ng/ml rh-GDF-9, 3 ng/ml Smad3 inhibitor,
and both rh-GDF-9 and Smad3 inhibitor, respectively. FAK
and paxillin mRNA levels were analysed using both conven-
tional and Q-PCR, and protein levels were analysed with
Western blotting. When the PC-3 cells were treated with rh-
GDF-9 alone, expression of FAK and paxillin was increased.
However, the up-regulation of both FAK and paxillin mRNA
and protein levels was inhibited when PC-3 cells were treated
with a Smad3 inhibitor. These levels were similar to those
seen in the untreated control. In addition, when these cells were
treated with both a Smad3 inhibitor and rh-GDF-9, FAK and
paxillin levels remained low, suggesting that GDF-9 signals
via Smad3 to up-regulate expression of these adhesion mole-
cules (Fig. 6).
Discussion
GDF-9 is a follicular growth factor vital during the early stages
of follicular development (11). Its role in cancer however is
unclear. We have previously shown that GDF-9 can inhibit
breast cancer cell invasiveness and that its expression corre-
lates with good prognosis (12). Conversely, a different group
demonstrated up-regulation of GDF-9 expression in more
aggressive oral squamous carcinoma cell lines, while another
reported GDF-9 up-regulation in lung adenocarcinoma cell
lines with silenced mutant P53, suggesting that GDF-9 may
aid in progression of these cancers (13,14).
This current study is the first to investigate the role of
GDF-9 on the biological properties of prostate cancer cells.
Our results show that by overexpressing endogenous GDF-9
in PC-3 cells, cell motility and adhesion was increased.
Treating PC-3 WT cells with rh-GDF-9 further showed that
exogenous GDF-9 can also promote the adhesive capacity of
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Figure 6. GDF-9 signalling via Smad3 regulates FAK and paxillin. PC-3 cells were treated with serum-free media, 20 ng/ml rh-GDF-9, 3 ng/ml Smad3
inhibitor or both rh-GDF-9 and Smad3 inhibitor, respectively. Western blot analysis showing (A) FAK and (B) paxillin protein levels in treated PC-3 cells.
The up-regulation in levels of FAK and paxillin associated with rh-GDF-9 was inhibited when cells were treated with Smad3 inhibitor. (C) FAK mRNA
levels were analysed using both normal and (D) Q-PCR. (E) Paxillin mRNA levels using normal and (F) Q-PCR.
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these cells. In addition, knocking-down GDF-9 in the same
cells resulted in the opposite and reduced effect of both
properties. These results suggest that GDF-9 plays an important
role in regulating prostate cancer cell adhesion and motility.
Furthermore, PC-3GDF-9exp. cells, and PC-3 WT cells treated
with rh-GDF-9, demonstrated with increased levels of FAK
and paxillin expression, focal adhesion-associated proteins
that transmit signals downstream of integrins. These down-
stream integrin signals are important in regulating cellular
properties including cell adhesion, migration, motility and
survival (15). Cell motility is a process involving changes in
actin filament dynamics and cell adhesion sites that lead to
the formation of membrane protrusions and traction forces
(15). FAK has been shown to influence the cytoskeleton, cell
adhesion structure sites, and membrane protrusions to regulate
cell movement (16). Paxillin meanwhile interacts with FAK
to recruit signal cascade molecules into close proximity in
order to allow for efficient signal transduction (17).
In addition to the up-regulation of FAK and paxillin,
GDF-9 also appeared to increase their phosphorylation and
activation. Phosphorylation of these molecules normally
occurs in response to integrin mediated cell adhesion and
growth factor stimulation (17). This suggests that GDF-9 may
act as a growth factor to stimulate up-regulation and
activation of FAK and paxillin, resulting in increased
prostate cancer cell adhesion and motility. Another BMP
that has been reported to have an effect on these molecules
is BMP-7. Primary cultures of chondrocytes treated with rh-
BMP-7, demonstrated an up-regulation of FAK and paxillin
expression (18). In PC-3 prostate cancer cells however, with
knocked out BMP-7 demonstrated enhanced immuno-
fluorescent staining of paxillin and FAK, and a promotion in
cell matrix adhesion, invasion and motility (19).
BMPs can signal via two different pathways; the Smad-
dependent and Smad-independent (4). For example, BMP-9
was recently shown to signal via Smad1 to inhibit PC-3 cell
growth, adhesion, invasion and migration (7). BMP-10 mean-
while was shown to have a similar effect on PC-3 cells, but via
the Smad-independent pathway (20). In the case of GDF-9,
we now show Smad dependent signalling via Smad3. PC-3
cells treated with rh-GDF-9 demonstrated increased protein
levels and enhanced immuno-fluorescent nuclear staining of
pSmad3. In addition, when PC-3 cells were treated with Smad3
inhibitor, the increased adhesive capacity and up-regulation of
FAK and paxillin seen by rh-GDF-9 treatment was inhibited,
suggesting that GDF-9 may signal via Smad3 to up-regulate
both FAK and paxillin in order to promote their adhesiveness.
In conclusion, this study shows that both endogenous and
exogenous GDF-9 can promote the adhesive and motile
capacity of PC-3 prostate cancer cells, through Smad-3-
dependent up-regulation and activation of focal adhesion
molecules, FAK and paxillin. These results imply that GDF-9
may act as a survival factor in prostate cancer, promoting
disease progression.
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